Analyst firms · Citigroup · SRPT
Citigroup SRPT price target and rating history
Sarepta Therapeutics Inc. (SRPT) · Health Care
Citigroup rates Sarepta Therapeutics Inc. (SRPT) Sell with a $7 price target, as of its latest action on Jul 24, 2025. It has published 4 rating actions on SRPT since April 2023, including 0 upgrades and 1 downgrade. Across 3 firms with a SRPT price target in the last 12 months, the median target is $27.
- Current rating
- Sell
- Price target
- $7
- Median target, all firms
- $27
- Actions on SRPT
- 4
Citigroup price target on SRPT
Every Citigroup rating on SRPT
- Jul 24, 2025
- Jun 26, 2024
- Dec 13, 2023
- Apr 4, 2023
How other firms rate SRPT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $27 | Jul 9, 2026 |
| Barclays | Equal Weight | $20 | Jan 28, 2026 |
| Wedbush | Outperform | $32 | Dec 9, 2025 |
Questions about Citigroup and SRPT
- What is Citigroup's price target for SRPT?
- Citigroup's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $7, from its action on Jul 24, 2025.
- What is Citigroup's rating on SRPT?
- Citigroup rates SRPT Sell, a bearish rating, as of Jul 24, 2025.
- When did Citigroup last change its view on SRPT?
- On Jul 24, 2025, Citigroup starts coverage at Sell, price target $7.
- How does Citigroup's SRPT target compare with other analysts?
- Across 3 firms with a SRPT price target in the last 12 months, the median target is $27.
More SRPT rating histories
- Barclays4
- BMO Capital Markets3
- Oppenheimer4
- H.C. Wainwright4
- Deutsche Bank3
- Needham5
- Morgan Stanley6
- Cantor Fitzgerald4
- RBC Capital Markets5
- Credit Suisse3
All Citigroup ratingsSRPT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.